Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24122008 | 0.72 | CHRM4 (0.36) | — | |
| SCHEMBL13841389 | 0.71 | LMNA (0.42) | NPC1 | |
| SCHEMBL2007373 | 0.70 | ADORA2A (0.32) | ADORA2A | |
| SCHEMBL4385353 | 0.70 | ADORA2A (0.37) | ADORA2A | |
| SCHEMBL314773 | 0.70 | ADORA2A (0.32) | ADORA2A | |
| SCHEMBL23618574 | 0.70 | ADORA2A (0.32) | ADORA2A | |
| SCHEMBL314774 | 0.70 | ADORA2A (0.32) | ADORA2A | |
| SCHEMBL2007375 | 0.70 | ADORA2A (0.52) | ADORA2A | |
| SCHEMBL4573957 | 0.70 | ADORA2A (0.32) | ADORA2A | |
| SCHEMBL28188932 | 0.70 | ADORA2A (0.37) | ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3960737-B1 | BENZOCARBAZOLE-BASED COMPOUNDS AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING THEM | LG CHEMICAL LTD (KR) | 2023-08-09 | — | — | EP | disclosed |
| US-20230172057-A1 | HETEROCYCLIC COMPOUND CONTAINING HETEROATOM SUBSTITUTED FLUORENE AND OPTOELECTRONIC DEVICE | WUHAN TIANMA MICRO-ELECTRONICS CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230138901-A1 | COMPOUND HAVING KHK INHIBITORY EFFECT | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| WO-2021254493-A1 | CYCLIC COMPOUND HAVING ANTI-TUMOR ACTIVITY AND USE THEREOF | 上海翊石医药科技有限公司 | 2021-12-23 | — | — | WO | disclosed |
| US-11173145-B2 | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-11-16 | — | — | US | disclosed |
| WO-2021129737-A1 | COMPOUND HAVING KHK INHIBITORY EFFECT | 南京明德新药研发有限公司 | 2021-07-01 | — | — | WO | disclosed |
| EP-3725785-A1 | GLUTARIMIDE DERIVATIVES, USE THEREOF, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHODS FOR PRODUCING GLUTARIMIDE DERIVATIVES | Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" (RU) | 2020-10-21 | — | — | EP | disclosed |
| EP-3722290-A1 | GLUTARIMIDE DERIVATIVES, USE THEREOF, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHODS FOR PRODUCING GLUTARIMIDE DERIVATIVES | Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" (RU) | 2020-10-14 | — | — | EP | disclosed |
| WO-2020018670-A1 | COMPOUNDS USEFUL AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN DIOXYGENASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-01-23 | — | — | WO | disclosed |
| US-10377739-B2 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives | Obschestvo S Ogranichennoi Otvetstvennostiyu “Pharmenterprises” (RU) | 2019-08-13 | — | — | US | disclosed |
| US-20070010669-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE | 2007-01-11 | — | — | US | disclosed |
| US-20070010669-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE | 2007-01-11 | — | — | US | disclosed |
| US-20060167103-A1 | Methods of treating cancer with HDAC inhibitors | ATON PHARMA, INC. (US) | 2006-07-27 | — | — | US | disclosed |
| US-20060167103-A1 | Methods of treating cancer with HDAC inhibitors | ATON PHARMA, INC. (US) | 2006-07-27 | — | — | US | disclosed |
| US-20040132825-A1 | Methods of treating cancer with HDAC inhibitors | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2004-07-08 | — | — | US | disclosed |
| US-20040132825-A1 | Methods of treating cancer with HDAC inhibitors | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2004-07-08 | — | — | US | disclosed |
| US-20040127523-A1 | safe, daily dosing regimen of histone deacetylase (HDAC) inhibitors having favorable pharmacokinetic profiles such as high bioavailability and surprisingly give rise to high blood levels of the active compounds over an extended period of time | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2004-07-01 | — | — | US | disclosed |
| US-20040127523-A1 | safe, daily dosing regimen of histone deacetylase (HDAC) inhibitors having favorable pharmacokinetic profiles such as high bioavailability and surprisingly give rise to high blood levels of the active compounds over an extended period of time | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2004-07-01 | — | — | US | disclosed |
| CN-1503793-A | N-substituted non-aryl-heterocyclic NMDA/NR2B antagonists | — | 2004-06-09 | — | — | CN | disclosed |
| WO-2003032921-A2 | TREATMENT OF NEURODEGENERATIVE DISEASES AND CANCER OF THE BRAIN | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377739-B2 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives | GCDH, GLS, HADH | ADORA2A 4321/4885CCR1 4310/4885CCR5 2619/4885 |
| US-20060167103-A1 | Methods of treating cancer with HDAC inhibitors | HDAC5, HDAC1, HDAC4 | ADORA2A 3875/4885CCR1 2516/4885CCR5 2417/4885 |
| US-20040127523-A1 | safe, daily dosing regimen of histone deacetylase (HDAC) inhibitors having favorable pharmacokinetic profiles such as high bioavailability and surprisingly give rise to high blood levels of the active compounds over an extended period of time | HDAC1, HDAC5, HDAC9 | ADORA2A 2466/4885CCR1 2270/4885CCR5 1770/4885 |
| US-20040132825-A1 | Methods of treating cancer with HDAC inhibitors | HDAC5, HDAC9, HDAC1 | ADORA2A 2200/4885CCR1 2051/4885CCR5 1989/4885 |
| US-20230172057-A1 | HETEROCYCLIC COMPOUND CONTAINING HETEROATOM SUBSTITUTED FLUORENE AND OPTOELECTRONIC DEVICE | CHRM1, CHRM2, CHRM4 | ADORA2A 654/4885CCR1 315/4885CCR5 600/4885 |
| US-20070010669-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | ACIN1, HDAC3, HDAC1 | ADORA2A 3033/4885CCR1 906/4885CCR5 1976/4885 |
| US-11173145-B2 | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase | TPH2, TPH1, IDO2 | ADORA2A 271/4885CCR1 4321/4885CCR5 2654/4885 |
| US-20230138901-A1 | COMPOUND HAVING KHK INHIBITORY EFFECT | KHK, KHDRBS1, KHSRP | ADORA2A 4466/4885CCR1 4755/4885CCR5 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.